You are here

Amarin

ESC 2019 – Amarin hopes for guideline boost despite regulatory delay

EP Vantage

Tue, 09/3/19 - 10:54 am

European Society of Cardiology

Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting

Fierce Pharma

Thu, 08/8/19 - 11:36 pm

advisory panels

Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom

Endpoints

Wed, 07/31/19 - 10:30 am

advisory panels

Amarin: Is a Buyout Really Off the Table?

Yahoo/Motley Fool

Sun, 07/21/19 - 04:17 pm

Acasti sits pretty as raise brings $400M for Amarin

BioWorld

Fri, 07/19/19 - 07:24 pm

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

Stat

Tue, 07/2/19 - 12:20 pm

Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?

Endpoints

Wed, 05/29/19 - 10:12 am

Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in

Fierce Pharma

Wed, 05/8/19 - 10:51 am

These 6 biotech stocks are promising takeover targets

Marketwatch

Thu, 05/2/19 - 11:33 am

Sarepta Therapeutics

Intercept Pharmaceuticals

Alder Biopharmaceuticals

Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up

Endpoints

Fri, 03/29/19 - 10:02 am

Diabetes group nods to Vascepa, sending Amarin stock higher

Biopharma Dive

Thu, 03/28/19 - 07:59 pm

Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate

Stat

Mon, 03/18/19 - 12:14 pm

American College of Cardiology

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Yahoo/Benzinga

Sat, 03/16/19 - 12:25 pm

SAGE Therapeutics

Ligand Pharmaceuticals

Jazz Pharmaceuticals

Lexicon Pharmaceuticals

Leap Therapeutics

ACC 2019 preview – Bayer hopes for heart failure panache

EP Vantage

Tue, 03/12/19 - 10:15 am

Is Amarin Sitting on a Goldmine?

Motley Fool

Thu, 02/28/19 - 09:18 pm

Would Pfizer Shareholders Win With an Acquisition of Amarin?

Motley Fool

Sun, 01/20/19 - 03:26 pm

Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs

Fierce Pharma

Sat, 01/12/19 - 11:37 am

The winners and losers from JPM 2019

Biopharma Dive

Fri, 01/11/19 - 11:51 am

SAGE Therapeutics

JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies

BioSpace

Thu, 01/10/19 - 08:48 pm

SAGE Therapeutics

Denali Therapeutics

government shutdown

Pharma's 2019 Prognosis Hinges on These Key Themes

Bloomberg

Wed, 01/2/19 - 09:48 pm

Pages